|
1
|
Arduino PG, Kubanov AA, Vlasova AV, Martynov AA, Svishchenko SI, Petti S. De novo pemphigus vulgaris and pemphigus foliaceus development following COVID-19 infection and vaccination: Matched case-control study. J Eur Acad Dermatol Venereol 2024; 38:e374-e376. [PMID: 38217309 DOI: 10.1111/jdv.19783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Accepted: 12/19/2023] [Indexed: 01/15/2024]
Affiliation(s)
- P G Arduino
- Department of Surgical Science, University of Turin, Turin, Italy
| | - A A Kubanov
- State Research Center of Dermatovenereology and Cosmetology, Moscow, Russian Federation
| | - A V Vlasova
- Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | - A A Martynov
- State Research Center of Dermatovenereology and Cosmetology, Moscow, Russian Federation
| | - S I Svishchenko
- State Research Center of Dermatovenereology and Cosmetology, Moscow, Russian Federation
| | - S Petti
- Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy
| |
Collapse
|
|
2
|
Tan AJ, Archila M, Barbieri JS, Mostaghimi A, Scherer AM, Perez-Chada LM, Asgari MM, Gelfand JM, Noe MH. Understanding patient perspectives on vaccine decision making in adults with autoimmune bullous diseases: a qualitative study. Arch Dermatol Res 2024; 316:125. [PMID: 38637431 DOI: 10.1007/s00403-024-02862-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 12/22/2023] [Accepted: 04/07/2024] [Indexed: 04/20/2024]
Abstract
Patients with autoimmune bullous diseases are at an increased risk of infection, both from the underlying skin disease and from immunosuppressive treatments. Limited information is available on vaccine beliefs and behaviors in dermatology patients and adults with autoimmune bullous diseases in particular. To understand vaccine decision making, identify perceived risks and benefits of vaccinations, and discuss individual experiences in patients with autoimmune bullous diseases in the United States. A qualitative study was performed utilizing semi-structured interviews, and analysis was conducted on NVivo. Patterns were identified in the coded data, and representative quotations were recorded for each major theme. Interviews were conducted between February 15, 2022 and September 15, 2022. Twenty patients with a diagnosis of bullous pemphigoid, mucous membrane pemphigoid, pemphigus vulgaris, or pemphigus foliaceous were interviewed. Of the 20 participants, 14 (70%) were female, with a mean (SD, range) age of 64.8 (13.2, 34-83) years. Key themes that emerged from qualitative analysis of the interviews included patient concerns regarding their increased susceptibility to infection, potential exacerbation of skin disease following vaccination, and the effect of immunosuppressive medications on humoral response to vaccines. Lack of appointment availability, difficulty accessing vaccines, and cost were commonly identified barriers to vaccination. These findings provide valuable knowledge for dermatologists in regard to providing counseling specific to patient concerns and to improve communication surrounding vaccination in the dermatology setting.
Collapse
Affiliation(s)
- Alice J Tan
- University of Massachusetts Medical School, Worcester, MA, USA
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA, 02215, USA
| | - Marjorie Archila
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA, 02215, USA
| | - John S Barbieri
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA, 02215, USA
| | - Arash Mostaghimi
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA, 02215, USA
| | - Aaron M Scherer
- Department of Internal Medicine, University of Iowa, Iowa City, IA, USA
| | - Lourdes M Perez-Chada
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA, 02215, USA
| | - Maryam M Asgari
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA
- Department of Population Medicine, Harvard Medical School, Boston, MA, USA
| | - Joel M Gelfand
- Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA
- Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA
| | - Megan H Noe
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA, 02215, USA.
| |
Collapse
|
|
3
|
Kasperkiewicz M, Woodley DT. COVID-19 and autoimmune bullous diseases: Lessons learned. Autoimmun Rev 2023; 22:103286. [PMID: 36738951 PMCID: PMC9893837 DOI: 10.1016/j.autrev.2023.103286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Accepted: 01/30/2023] [Indexed: 02/05/2023]
Abstract
Both COVID-19 and autoimmune bullous diseases represent potentially life-threatening conditions. Autoimmunity has been a special focus during the COVID-19 pandemic considering the possible detrimental mutual influence between COVID-19 and autoimmune disorders as well as their supposed induction or triggering by SARS-CoV-2 vaccines. There is a growing need to assess the impact of the current pandemic particularly in patients with autoimmune bullous diseases requiring potent and long-term immunosuppressive treatments. This review provides the relevant state-of-the-art knowledge, including our own research, about immunobullous diseases in relation to COVID-19 and summarizes expert perspectives on their management throughout the pandemic.
Collapse
Affiliation(s)
- Michael Kasperkiewicz
- Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
| | - David T Woodley
- Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| |
Collapse
|